Printer Friendly

IMMULOGIC FILES REGISTRATION STATEMENT WITH SEC TO SELL 2 MILLION SHARES OF COMMON STOCK

 IMMULOGIC FILES REGISTRATION STATEMENT WITH SEC TO SELL
 2 MILLION SHARES OF COMMON STOCK
 CAMBRIDGE, Mass., Dec. 20 /PRNewswire/ -- ImmuLogic Pharmaceutical Company (NASDAQ: IMUL) today announced that it has filed a registration statement with the Securities and Exchange Commission relating to a public offering of 2 million shares of its common stock. Morgan Stanley & Co. Incorporated and Hambrecht & Quist Incorporated will manage the offering.
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing a family of ALLERVAX(tm) products to treat allergic diseases and the company has recently announced an agreement with Marion Merrell Dow Inc. (NYSE: MKC) to collaborate on the worldwide commercialization of these products. The company is also collaborating with Merck & Co. (NYSE: MRK) to develop treatments for Type I diabetes and rheumatoid arthritis.
 The company intends to use the net proceeds from the offering to fund research, development and clinical programs; expand and relocate its facilities, and other general corporate purposes.
 ImmuLogic will grant to the underwriters an option to purchase up to 300,000 shares of common stock solely to cover overallotments, if any.
 A written prospectus may be obtained from the managing underwriters, Morgan Stanley & Co. Incorporated, 1251 Avenue of the Americas, New York, N.Y. 10020, or Hambrecht and Quist Corporation, One Bush St., San Francisco, Calif. 94104, 415-576-3626.
 ---
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 -0- 12/20/91
 /CONTACT: Janet C. Bush, vice president-finance and administration, of ImmuLogic Pharmaceutical Corp., 617-494-0060/
 (IMUL MKC MRK) CO: ImmuLogic Pharmaceutical Corporation ST: Massachusetts IN: MTC SU: OFR


PB-SH -- NE004 -- 4261 12/20/91 09:55 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:378
Previous Article:HALIFAX CORPORATION AWARDED ARMY CONTRACT
Next Article:BELLSOUTH ENTERPRISES TO ACQUIRE SCIENTIFIC SOFTWARE
Topics:


Related Articles
VERTEX PHARMACEUTICALS INTENDS TO FILE REGISTRATION STATEMENT WITH SEC TO SELL 2 MILLION SHARES OF COMMON STOCK
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC ANNOUNCES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK AT $22.75 PER SHARE
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
ANERGEN ANNOUNCES FINANCING PLANS
ImmuLogic Reports Fourth Quarter And Year-End 1996 Financial Results
Endo Files Shelf Registration Statement for Secondary Sale of 19 Million Currently Issued and Outstanding Shares of Common Stock.
Tercica Secures $75 Million Committed Equity Financing Facility.
InterMune Announces Filing of Shelf Registration Statement.
Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters